Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Date:1/13/2009

NEW YORK, Jan. 13 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc. (BLU: TSX). The full 52-page report can be found at www.crystalra.com.

BELLUS Health Inc. ("BELLUS Health" or "the Company") is a global health company focused on providing innovative pharmaceutical and nutraceutical solutions for critical unmet needs. BELLUS Health aims to generate revenue in the short to medium term through the marketing and sale of branded nutraceutical products, thus enabling the medium- to long-term development and commercialization of its pharmaceutical pipeline. The Company's pharmaceutical products target disorders with no known cures and limited treatments. BELLUS Health's most advanced pharmaceutical candidate is KIACTA(TM) (eprodisate), a Phase III compound to treat Amyloid A (AA) amyloidosis, a disease marked by an accumulation of abnormal proteins that can lead to organ failure and death. In a Phase II/III trial of eprodisate, patients on KIACTA(TM) (eprodisate) had a lower risk of progression of AA amyloidosis-related renal disease and a slower rate of decline in creatinine clearance (a reduction in clearance indicates worsened renal disease). BELLUS Health expects to file a new protocol amendment to the Investigational New Drug (IND) application for the second pivotal Phase III clinical trial of KIACTA(TM) in the first quarter 2009.

The Company's other pharmaceutical developments include NC-503 (eprodisate), which is currently in a proof-of-concept Phase II study in patients with Type II diabetes and certain features of metabolic syndrome, and a prodrug program for Alzheimer's disease (AD), which is at the preclinical development stage. The Company, through its wholly owned subsidiary, OVOS Natural Health Inc., is also commercializing a condition-specific, clinically tested branded nutraceutical to protect memory. This first product, VIVIMIND(TM), was launched in Canada in September 2008 and is also available via the Internet. The Company plans to market VIVIMIND(TM) in the U.S. in 2009 and in the EU in 2011.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of fifty thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed may constitute forward-looking statements as defined by applicable securities legislation. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC or SEDAR.

These statements and other forward-looking statements involve numerous risks and uncertainties, known and unknown. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited
2. Crystallography reveals the 3-D structure of mammalian sperm receptor
3. Asia Wellness Cruise Offers Crystal Guests Peace of Mind, Body & Spirit
4. Crystalens HD(TM) Receives FDA Approval
5. Success for Crystal Meth Drug Addict on YouTube
6. Steve and Paula Mae Schwartz Honored With Publicity Club of New Englands Crystal Bell Award
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
9. Measurement technique probes surface structure of gold nanocrystals
10. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
11. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: